reglab/housing_qa huggingface dataset:
CA Health & Safety Code § 127673.84 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 8.5 - Health Care Payments Data Program|Section 127673.84.

127673.84.  (a) The department shall establish a data release committee with a membership of at least 7 and no more than 11 members appointed by the director. Notwithstanding any other law, a quorum shall be achieved with one fewer member than one-half of the full membership.(b) The appointed members shall include representatives of health care payers, providers, suppliers, purchasers, researchers, consumers, and labor. Representatives of program data submitters shall not constitute a majority of members. The members shall have knowledge and experience with health care data, privacy, and security.(c) Each appointed member shall serve a term of two years, except one-half of the initial appointments shall be for one year. The director may remove a member for cause.(d) (1) The data release committee shall make recommendations about all applications seeking either program data with direct personal identifiers or the transmission of standardized datasets, except for data requests from other state agencies. Upon request of the director, the data release committee shall also make recommendations about other applications for program data.(2) In making recommendations about applications seeking program data, except for data requests from other state agencies, the data release committee shall consider whether the use of the data is consistent with the goals of the system, whether it provides greater transparency regarding health care costs, utilization, quality, or equity, or how the information may be used to inform policy decisions regarding the provision of quality health care, improving public health, reducing health disparities, advancing health coverage, or reducing health care costs.(e) Upon request of the director, the data release committee shall generally advise the director about privacy and security matters related to the program and provide feedback on the program’s data application review processes and other matters.(f) The chairperson of the data release committee shall be appointed from among the members by the director.(g) A member of the data release committee appointed from outside state government shall serve without compensation, but shall receive a per diem for each day’s attendance at a data release committee meeting. All members shall be reimbursed for any actual and necessary expenses incurred in connection with their duties as members of the committee.(Amended by Stats. 2021, Ch. 143, Sec. 106. (AB 133) Effective July 27, 2021.)
CA Health & Safety Code § 127674 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 8.5 - Health Care Payments Data Program|Section 127674.

127674.  (a) The department shall expend the General Fund moneys appropriated in the 2018–19 Budget Act (Chapter 23 of the Statutes of 2019) for the purposes of this chapter and the former Health Care Transparency Database to fund the implementation and operation of the program.(b) The Health Care Payments Data Program shall not be funded with General Fund moneys beyond moneys appropriated in the 2018–19 Budget Act.(c) The Health Care Payments Data Fund is hereby established within the department for the purpose of receiving and expending revenues collected pursuant to this chapter.(d) All revenues collected pursuant to this chapter shall be deposited in the fund. Any amounts raised by the collection of the revenues shall remain in the fund and shall be available in succeeding years upon appropriation by the Legislature.(e) The department shall seek to maximize federal financial participation from the Medicaid program for the system, working through the sole state agency for Medicaid, the State Department of Health Care Services, and shall do so while relying on moneys appropriated from the General Fund in the 2018–19 Budget Act, and on an ongoing basis using any federally allowed fund source for the state match.(f) (1) The department may impose a data user fee for an eligible user that is in compliance with this chapter, including, but not limited to, provisions related to consumer privacy and data security.(2) In establishing the user fee schedule and fee waivers, the department shall work with the advisory committee to make considerations for state agencies, data submitters, and consumer organizations that have been awarded reasonable advocacy and witness fees in a proceeding or proceedings of the Department of Managed Health Care pursuant to Section 1348.9.(3) The department shall adopt regulations on the fee waiver consistent with subdivisions (e) and (f) of Section 127673.(g) On or before March 1, 2023, the office shall submit a report to the Legislature on recommendations for funding options for the program pursuant to Section 9795 of the Government Code.(h) The department may accept foundation funding from foundations not affiliated or controlled by a health care entity.(Amended by Stats. 2021, Ch. 143, Sec. 107. (AB 133) Effective July 27, 2021.)
CA Health & Safety Code § 127674.1 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 8.5 - Health Care Payments Data Program|Section 127674.1.

127674.1.  The department shall notify the Department of Managed Health Care or the Department of Insurance, as appropriate, if a health care service plan or health insurer fails to comply with this chapter. The Department of Managed Health Care and the Department of Insurance shall take appropriate action necessary to bring the plan or insurer into compliance.(Amended by Stats. 2021, Ch. 143, Sec. 108. (AB 133) Effective July 27, 2021.)
CA Health & Safety Code § 127675 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 9 - Prescription Drug Pricing for Purchasers|Section 127675.

127675.  (a) This chapter shall apply to a manufacturer of a prescription drug that is purchased or reimbursed by any of the following:(1) A state purchaser in California, including, but not limited to, the Public Employees’ Retirement System, the State Department of Health Care Services, the Department of General Services, and the Department of Corrections and Rehabilitation, or an entity acting on behalf of a state purchaser.(2) A licensed health care service plan.(3) A health insurer holding a valid outstanding certificate of authority from the Insurance Commissioner.(4) A pharmacy benefit manager as defined in subdivision (j) of Section 4430 of the Business and Professions Code.(b) For the purposes of this chapter, the term “department” shall mean the Department of Health Care Access and Information.(Amended by Stats. 2021, Ch. 143, Sec. 109. (AB 133) Effective July 27, 2021.)
CA Health & Safety Code § 127676 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 9 - Prescription Drug Pricing for Purchasers|Section 127676.

127676.  (a) The Legislature finds and declares that the State of California has a substantial public interest in the price and cost of prescription drugs. California is a major purchaser through the Public Employees’ Retirement System, the State Department of Health Care Services, the Department of General Services, the Department of Corrections and Rehabilitation, and other entities acting on behalf of a state purchaser. California also provides major tax expenditures through the tax exclusion of employer sponsored coverage and tax deductibility of coverage purchased by individuals, as well as tax deductibility of excess health care costs for individuals and families.(b) (1) It is the intent of the Legislature in enacting this chapter to provide notice and disclosure of information relating to the cost and pricing of prescription drugs in order to provide accountability to the state for prescription drug pricing.(2) It is further the intent of the Legislature to permit a manufacturer of a prescription drug to voluntarily make pricing decisions regarding a prescription drug, including any price increases. It is further the intent of the Legislature to permit purchasers, both public and private, as well as pharmacy benefit managers, to negotiate discounts and rebates consistent with existing state and federal law.(Added by Stats. 2017, Ch. 603, Sec. 4. (SB 17) Effective January 1, 2018.)
CA Health & Safety Code § 127677 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 9 - Prescription Drug Pricing for Purchasers|Section 127677.

127677.  (a) A manufacturer of a prescription drug with a wholesale acquisition cost of more than forty dollars ($40) for a course of therapy shall notify each purchaser described in Section 127675 if the increase in the wholesale acquisition cost of a prescription drug is more than 16 percent, including the proposed increase and the cumulative increases that occurred within the previous two calendar years prior to the current year. For purposes of this section, a “course of therapy” is defined as either of the following:(1) The recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for 30 days.(2) The recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for a normal course of treatment that is less than 30 days.(b) The notice required by subdivision (a) shall be provided in writing at least 60 days prior to the planned effective date of the increase.(c) (1) The notice required by subdivision (a) shall include the date of the increase, the current wholesale acquisition cost of the prescription drug, and the dollar amount of the future increase in the wholesale acquisition cost of the prescription drug.(2) The notice required by subdivision (a) shall include a statement regarding whether a change or improvement in the drug necessitates the price increase. If so, the manufacturer shall describe the change or improvement.(d) The notice required by subdivision (a) shall be provided to each state purchaser and other purchasers described in paragraphs (2) to (4), inclusive, of subdivision (a) of Section 127675 if a purchaser registers with the department for the purpose of this notification. The department shall make available to manufacturers a list of registered purchasers for the purpose of this notification.(e) If a pharmacy benefit manager receives a notice of an increase in wholesale acquisition cost consistent with subdivision (a), it shall notify its large contracting public and private purchasers of the increase. For the purposes of this section, a “large purchaser” means a purchaser that provides coverage to more than 500 covered lives.(Amended by Stats. 2021, Ch. 143, Sec. 110. (AB 133) Effective July 27, 2021.)
CA Health & Safety Code § 127681 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 9 - Prescription Drug Pricing for Purchasers|Section 127681.

127681.  (a) A manufacturer of a prescription drug shall notify the department in writing if it is introducing a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)). The notice shall be provided in writing within three days after the release of the drug in the commercial market. A manufacturer may make this notification pending approval by the federal Food and Drug Administration, if commercial availability is expected within three days of approval.(b) No later than 30 days after notification pursuant to this section, a manufacturer shall report all of the following information to the department in a format prescribed by the department:(1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally.(2) The estimated volume of patients that may be prescribed the drug.(3) If the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to final approval.(4) The date and price of acquisition if the drug was not developed by the manufacturer.(c) The manufacturer may limit the information reported pursuant to subdivision (b) to that which is otherwise in the public domain or publicly available.(d) The department shall publish the information provided to it pursuant to this section on its internet website on no less than a quarterly basis. The information shall be published in a manner that identifies the information that is disclosed on a per-drug basis and shall not be aggregated in a manner that would not allow identification of the drug.(e) The department shall be responsible for the enforcement of this section.(f) A manufacturer of a prescription drug subject to this chapter that does not report the information required pursuant to this section is liable for a civil penalty of one thousand dollars ($1,000) per day for every day after the notification period described in this section that the required information is not reported.(g) A civil penalty shall be assessed and recovered in a civil action brought by the department in the name of the people of the State of California. Assessment of a civil penalty may, at the request of any manufacturer of a prescription drug subject to this section, be reviewed on appeal, and the penalty may be reduced or waived for good cause.(h) Any money received by the department pursuant to this section shall be paid into the Managed Care Fund.(Amended by Stats. 2021, Ch. 143, Sec. 112. (AB 133) Effective July 27, 2021.)
CA Health & Safety Code § 127683 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 9 - Prescription Drug Pricing for Purchasers|Section 127683.

127683.  (a) Funding for the actual and necessary expenses of the department to conduct the activities described in this section and in Sections 127676, 127679, 127681, and 127685, shall be provided, subject to appropriation by the Legislature, from transfers of moneys from the Managed Care Fund and the Insurance Fund.(b) The share of funding from the Managed Care Fund shall be based on the number of covered lives in the state that are covered under plans regulated by the Department of Managed Health Care, including covered lives under Medi-Cal managed care, as determined by the Department of Managed Health Care, in proportion to the total number of all covered lives in the state.(c) The share of funding to be provided from the Insurance Fund shall be based on the number of covered lives in the state that are covered under health insurance policies and benefit plans regulated by the Department of Insurance, including covered lives under Medicare supplement plans, as determined by the Department of Insurance, in proportion to the total number of all covered lives in the state.(Amended by Stats. 2021, Ch. 143, Sec. 113. (AB 133) Effective July 27, 2021.)
CA Health & Safety Code § 127685 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 9 - Prescription Drug Pricing for Purchasers|Section 127685.

127685.  (a) The department may adopt regulations or issue guidance for the implementation of this chapter. All information that is required to be reported to the department pursuant to this chapter shall be reported in a form prescribed by the department, commencing in the first calendar quarter of 2019.(b) The department may consult with the Department of Managed Health Care, the Department of Insurance, the California State Board of Pharmacy, and any state purchaser of prescription drugs, or an entity acting on behalf of a state purchaser, in issuing guidance or adopting necessary regulations pursuant to subdivision (a), in posting information on its internet website pursuant to this chapter, and in taking any other action for the purpose of implementing this chapter.(Amended by Stats. 2021, Ch. 143, Sec. 114. (AB 133) Effective July 27, 2021.)
CA Health & Safety Code § 127686 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 9 - Prescription Drug Pricing for Purchasers|Section 127686.

127686.  (a) By January 1, 2022, the California Research Bureau shall report to the Legislature on the implementation of this chapter, including, but not limited to, this chapter’s effectiveness in addressing the following goals:(1) Promoting transparency in pharmaceutical pricing for the state and other payers.(2) Enhancing understanding about pharmaceutical spending trends.(3) Assisting the state and other payers in management of pharmaceutical drug costs.(b) A report submitted pursuant to subdivision (a) shall be submitted in compliance with Section 9795 of the Government Code.(c) Notwithstanding any other law, implementation of this chapter shall be subject to review by the appropriate policy committees of the Legislature. The review shall be performed as if this chapter were scheduled to be repealed on January 1, 2023.(d) This section shall remain in effect only until January 1, 2024, and as of that date is repealed.(Added by Stats. 2017, Ch. 603, Sec. 4. (SB 17) Effective January 1, 2018. Repealed January 1, 2024, by its own provisions.)
CA Health & Safety Code § 127690 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 10 - California Affordable Drug Manufacturing Act of 2020|Section 127690.

127690.  This chapter may be cited as the California Affordable Drug Manufacturing Act of 2020.(Added by Stats. 2020, Ch. 207, Sec. 1. (SB 852) Effective January 1, 2021.)
CA Health & Safety Code § 127691 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 10 - California Affordable Drug Manufacturing Act of 2020|Section 127691.

127691.  For purposes of this chapter, the following definitions shall apply:(a) “Generic drug” means a drug that is approved pursuant to subdivision (j) of Section 355 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 301 et seq.), or a biosimilar, as defined under the federal Public Health Service Act (42 U.S.C. Sec. 262). (b) “Partnerships” include, but are not limited to, agreements for the procurement of generic prescription drugs by way of contracts or purchasing by a payer, state governmental agency, group purchasing organization, nonprofit organization, or other entity.(Added by Stats. 2020, Ch. 207, Sec. 1. (SB 852) Effective January 1, 2021.)
CA Health & Safety Code § 127692 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 10 - California Affordable Drug Manufacturing Act of 2020|Section 127692.

127692.  (a) The California Health and Human Services Agency (CHHSA) shall enter into partnerships, consistent with subdivision (b) of Section 127693, in consultation with other state departments as necessary, to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.(b) CHHSA shall have the ability to hire staff to oversee and project-manage the partnerships for manufacturing or distribution of generic prescription drugs, contingent upon an appropriation by the Legislature for this purpose.(Added by Stats. 2020, Ch. 207, Sec. 1. (SB 852) Effective January 1, 2021.)
CA Health & Safety Code § 127694 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 10 - California Affordable Drug Manufacturing Act of 2020|Section 127694.

127694.  (a) On or before July 1, 2023, CHHSA shall submit a report to the Legislature that assesses the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price. The report shall include an analysis of governance structure options for manufacturing functions, including chartering a private organization, a public-private partnership, or a public board of directors.(b) This section shall only go into effect if the Legislature appropriates funds for this purpose in the annual budget.(c) The report shall be submitted in compliance with Section 9795 of the Government Code.(d) This section shall remain in effect only until January 1, 2025, and as of that date is repealed.(Added by Stats. 2020, Ch. 207, Sec. 1. (SB 852) Effective January 1, 2021. Repealed as of January 1, 2025, by its own provisions.)
CA Health & Safety Code § 127695 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 10 - California Affordable Drug Manufacturing Act of 2020|Section 127695.

127695.  (a) On or before July 1, 2022, CHHSA shall report to the Legislature on both of the following:(1) A description of the status of all drugs targeted under this chapter.(2) An analysis of how the activities of CHHSA may impact competition, access to targeted drugs, the costs of those drugs, and the costs of generic prescription drugs to public and private purchasers.(b) This section shall remain in effect only until January 1, 2026, and as of that date is repealed.(Added by Stats. 2020, Ch. 207, Sec. 1. (SB 852) Effective January 1, 2021. Repealed as of January 1, 2026, by its own provisions.)
CA Health & Safety Code § 127696 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 107 - HEALTH CARE ACCESS AND INFORMATION|PART 2 - HEALTH POLICY AND PLANNING|CHAPTER 10 - California Affordable Drug Manufacturing Act of 2020|Section 127696.

127696.  In order to protect proprietary, confidential information regarding manufacturer or distribution costs and drug pricing, utilization, and rebates, it is necessary that this act limit the public’s right of access to that information. Notwithstanding any other provision of law, all nonpublic information and documents obtained under this section shall not be required to be disclosed pursuant to the California Public Records Act, Chapter 3.5 (commencing with Section 6250) of Division 7 of Title 1 of the Government Code, or any similar local law requiring the disclosure of public records. (Added by Stats. 2020, Ch. 207, Sec. 1. (SB 852) Effective January 1, 2021. Superseded on January 1, 2023; see amendment by Stats. 2021, Ch. 615.)